ArticleThe Journal of clinical endocrinology and metabolism2025
Omega-3 Polyunsaturated Fatty Acids And Adipose Tissue Inflammation: Longitudinal Analysis in the PROMISE Cohort.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Replacement of Soybean Oil withAnimals : an open access journal from MDPI · 2026Article
- Article
- Omega-3 Polyunsaturated Fatty Acids And Adipose Tissue Inflammation: Longitudinal Analysis in the PROMISE Cohort.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesAlthough preclinical studies have shown a beneficial impact of omega-3 (n-3) polyunsaturated fatty acids (PUFAs) on adipose tissue (AT) inflammation, the current literature from human studies is limited. Therefore, we aimed to evaluate the longitudinal associations of circulating levels of n-3 PUFAs with biomarkers of AT inflammation.
methodsLongitudinal data from participants in the PROMISE cohort (n = 474) were used. AT inflammation was measured using circulating biomarkers at baseline and up to 2 follow-up visits. n-3 PUFAs were measured at baseline in 4 serum lipid fractions. Generalized estimating equations analyses evaluated longitudinal associations between n-3 PUFAs and AT inflammation, adjusting for covariates.
resultsFully adjusted generalized estimating equation models indicated that higher baseline proportions of eicosapentaenoic acid, n-3 docosapentaenoic acid, and docosahexaenoic acid in total serum were significantly inversely associated with longitudinal change in soluble CD163 (all P < .05). A significant positive association of n-3 docosapentaenoic acid and docosahexaenoic acid with longitudinal change in adiponectin (P < .05) was also observed. Generally consistent associations were observed between n-3 PUFAs and soluble CD163 and adiponectin in the four lipid fractions.
conclusionThese findings will add to the limited evidence on the potential role n-3 PUFAs have in the prevention and management of AT inflammation in humans and may help inform future interventions targeting chronic inflammation at the level of AT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.